Purpose: Obesity has become a global metabolic epidemic, closely linked to gastrointestinal function, gut hormones, and metabolic health. Bariatric endoscopy and hormone-based therapies offer minimally invasive, effective solutions for weight management and obesity-related GI disorders. Advances in endoscopic weight-loss procedures, gut hormone modulation (such as GLP-1–based therapies), and metabolic interventions have created a rapidly expanding market.
Upload here: https://gastroenterology-hepatology.utilitarianevents.com/upload-presentation/
WhatsApp: https://wa.me/+971551792927
Email: info-ucg@utilitarianconferences.com
Keynote Points:
Rapid growth of the global obesity and metabolic health market
Increasing adoption of minimally invasive bariatric endoscopic procedures
Strong demand for gut hormone–based and metabolic therapies
Expansion of integrated weight-management and metabolic clinics
Opportunities in endoscopic devices, consumables, and aftercare programs
Collaboration potential between GI, endocrinology, nutrition, and digital health sectors
Rising patient preference for non-surgical, scalable weight-loss solutions
Benefits:
High-revenue procedures with strong patient demand and repeat engagement
Attractive ROI for bariatric endoscopy centers and device manufacturers
Long-term revenue through follow-up care, nutrition, and lifestyle programs
Differentiation through comprehensive, multidisciplinary obesity management models
Strong investor interest in metabolic and hormone-based therapies
Positions businesses at the forefront of obesity and metabolic GI innovation